005690.KS
Pharmicell Co., Ltd.
KSC · Healthcare · Biotechnology · KR
KRW 10,380.00
−1.61%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 135.9B | 114.1B | 64.9B | 56.2B | 60.2B |
| Cost of Revenue | 76.0B | 64.0B | 43.5B | 41.3B | 36.4B |
| Gross Profit | 59.9B | 50.0B | 21.3B | 15.0B | 23.8B |
| Operating Expenses | |||||
| R&D Expense | 7.1B | 7.2B | 7.9B | 6.9B | 6.9B |
| SG&A Expense | 8.9B | 3.4B | 3.2B | 3.0B | 2.4B |
| General & Admin Expense | 4.7B | 2.2B | 2.0B | 1.6B | 1.5B |
| Selling & Marketing Expense | 774.8M | 1.2B | 1.2B | 1.3B | 908.5M |
| Other Expenses | 1.9B | 5.7B | 5.6B | 4.2B | 5.6B |
| Total Operating Expenses | 15.9B | 16.2B | 16.7B | 14.0B | 14.9B |
| Cost and Expenses | 91.9B | 79.7B | 60.2B | 55.3B | 51.3B |
| Operating Income (EBIT) | 44.0B | 33.8B | 4.7B | 951.0M | 8.9B |
| Non-Operating | |||||
| Interest Income | 1.8B | 770.6M | 254.2M | 273.8M | 330.8M |
| Interest Expense | 978.2M | 145.2M | 101.4M | 866.9M | 746.2M |
| Net Interest Income | 824.2M | 625.3M | 152.9M | (593.1M) | (415.4M) |
| Other Non-Op Income/Expense | 2.9B | 463.3M | 1.6B | 3.8B | (2.9B) |
| Non-Operating Income (excl Interest) | (608.6M) | — | (1.7B) | (4.6B) | 2.2B |
| EBT (Pre-Tax Income) | 47.0B | 34.8B | 6.3B | 4.7B | 6.0B |
| Income Tax Expense | 380.7M | (5.5B) | (67.3M) | 1.2B | (2.3B) |
| Bottom Line | |||||
| Net Income | 46.6B | 40.3B | 6.3B | 3.6B | 8.3B |
| Earnings from Cont. Ops | 46.6B | 40.3B | 6.3B | 3.6B | 8.3B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 46.6B | 40.3B | 6.3B | 3.6B | 8.3B |
| Per Share | |||||
| Basic EPS | ₩776 | ₩672 | ₩106 | ₩60 | ₩138 |
| Diluted EPS | ₩776 | ₩672 | ₩106 | ₩60 | ₩138 |
| Revenue Per Share | ₩2,266 | ₩1,900 | ₩1,081 | ₩943 | ₩1,004 |
| Shares | |||||
| Basic Shares Outstanding | 60.0M | 60.0M | 60.0M | 59.6M | 60.0M |
| Diluted Shares Outstanding | 60.0M | 60.0M | 60.0M | 60.0M | 60.0M |
| Profitability Metrics | |||||
| EBITDA | 47.0B | 36.8B | 9.4B | 8.4B | 8.9B |
| D&A | 3.0B | 3.0B | 3.1B | 2.8B | 2.2B |
| EBIT | 44.0B | 33.8B | 6.4B | 5.6B | 6.7B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026